Using lanthanide ions in molecular bioimaging by Amoroso, Angelo James & Pope, Simon J. A.
  
 
 
 
 
 
 
 
 
  
 
Using lanthanide ions in molecular bioimaging 
  
 
 
 
 
 
Angelo J. Amoroso* and Simon J. A. Pope* 
 
Trivalent lanthanide ions oﬀer remarkable opportunities in the design of bioimaging agents: this review 
presents an accessible discussion of their application in both optical and magnetic resonance imaging. 
Aspects of molecular design, control over key physical properties and biological compatibility are discussed 
in this context, together with developments and opportunities as responsive probes and in multimodal 
imaging. 
  
1. Introduction 
 
In recent years, a number of highly informative and compre-
hensively inclusive reviews have been written addressing the areas 
of luminescence and magnetic resonance imaging (MRI).
1
 
Furthermore, some of these reviews have focussed on the use of 
lanthanides ions in these applications.
2
 With this in mind, this 
review aims to introduce the general reader (in particular 
undergraduate and graduate students) to the area of lanthanide ions 
for luminescence and/or MRI applications, clarify some general 
misconceptions and give an indication of current directions in these 
areas of research. The subject area is far too broad for this review to 
be comprehensive
3
 and we have chosen only illustrative examples of 
molecular probes for the  
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reader; we can only apologise to the authors of other excellent 
examples that we have omitted. At times the subject topic will also 
reference apparently daunting physical equations. We have, where 
possible, tried to avoid such references and instead explain their 
relevance to the chemist involved in the design and synthesis of such 
compounds. The discussion will cover optical properties and 
luminescence imaging applications, MRI and finally the 
opportunities oﬀ ered in multimodal imaging. 
 
2. Luminescence imaging with 
lanthanide ions 
 
Fluorescence microscopy is a rapidly developing optical ima-ging 
technique ideal for analysing biological samples at high resolution 
such that individual cells can be imaged. Diﬀ raction-limited 
microscopy has an image resolution of ca. 200–250 nm; 
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further developments in hardware and software facilitate super-
resolved fluorescence microscopy at ca. 20–100 nm image 
resolution (an area recognised with the 2014 Nobel Prize in 
Chemistry
4
), rendering sub-cellular components in remarkable 
detail. Fluorescent organic molecules dominate the commer-cial 
market for cell imaging agents, with a wide range of labels and 
fluorescent proteins available, although biocompatible quantum dots 
are also gaining in popularity. For luminescent molecules, the 
absorption and emission wavelengths (labs and lem), observed 
lifetime (tobs) and the quantum yield (f) are key physical parameters 
that describe the luminescence. Typically the emitted photon 
possesses a lower energy than the absorbed photon (labs o lem) and 
this difference in wavelengths is defined as the Stokes’ shift. 
Consideration of these parameters is critical to the application of 
luminescent molecules in biological imaging. However, there are 
significant photophysical and biological advantages to the use of f-
metal ion coordination complexes in such applications. In particular, 
exciting opportu-nities are afforded by luminescent Ln(III)-based 
systems (large Stokes’ shifts; long luminescent lifetimes 41 ms) and 
this section will discuss some of the key developments that have 
allowed their application.
5 
 
Relevant microscopy applications 
 
Confocal fluorescence microscopy (CFM) is a powerful optical 
technique that makes use of luminescence (in this case the term 
fluorescence is misleading as phosphorescence can also be utilised 
in CFM) to generate the image. It is possible to obtain confocal 
fluorescence microscopes with a range of diﬀ erent light excitation 
sources (e.g. lamps, lasers and LEDs), which, together with suitable 
optics, can deliver a monochromated wavelength to the sample. The 
use of NIR light allows better light penetration and improved 
imaging depth.
6
 Multi-photon excitation sources are now also 
available, potentially allowing low energy (e.g. NIR) irradiation of 
samples. For reference, the two-photon absorption (TPA) cross 
section is defined as s2PA(l) and is given in GM (where GM = 
Goeppert-Mayer unit; 10 
50
 cm
4
 s per photon per molecule). The 
magnitudes of two-and three-photon cross sections thus determine 
the required light intensity for excitation and may constrain 
bioapplicability of a given probe; typical TPA values for organic 
chromophores are 10–100 GM, but higher TPA cross-sections 
facilitate lower irradiating light intensities.
7
 Significant progress has 
been made in recent years with the utility of Ln(III) complexes and 
optimized cross-sections.
8–10 
 
Fluorescence lifetime imaging microscopy (FLIM) is a more 
advanced form of the technique and creates the image based on the 
emission lifetime rather than the intensity of the signal. A pulsed 
light source is required and FLIM commonly employs time-
correlated single-photon counting (TCSPC); modern microscopes 
can have picosecond resolution. The principal advantage of FLIM is 
that it can deliver quantitative informa-tion since the lifetime of the 
probe is independent of its concentration, providing measurement of 
dynamic events and an ability to monitor cellular compartments with 
good spatial resolution.
3
 The equivalent approach that makes 
explicit use of 
 
phosphorescent probes, such as relevant metal complexes, is termed 
PLIM. In a subtle variation, gated microscopy allows the 
luminescence signal to be collected after a prescribed time delay, 
which is particularly useful for removing short-lived fluorescence (t 
o 20 ns) from endogenous (biological) fluorophores. 
 
 
A brief description of lanthanide ion luminescence 
 
Upon irradiation (Scheme 1) with an appropriate wavelength, a light-
absorbing species (termed the antenna) will convert to its singlet 
electronically excited state (S1); radiative decay from this state can 
occur via fluorescence (i.e. the molecule is a fluoro-phore) and is 
typically short-lived (commonly o 50 ns). Alter-natively, intersystem 
crossing (ISC; mediated by a number of processes including spin–
orbit coupling and heavy atom effects) can generate the lower lying 
triplet excited state (T1). This is a spin-forbidden process since DS a 
0 and radiative decay from the triplet state to the ground state is 
slow, occurring via phosphorescence. Due to the spin-forbidden 
nature of the radiative relaxation, the T1 state can be very long-lived 
and susceptible to other non-radiative processes, including 
quenching by molecular oxygen. 
 
Most luminescent organic molecules emit light without any 
change in spin-state (i.e. S1 - S0; fluorescence), and thus gen-erally 
possess relatively small Stokes’ shifts (e.g. o3000 cm 
1
).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 Top: simplified model for describing a common mechanism for 
sensitized lanthanide luminescence. Bottom: typical energy level diagram 
for an emissive chromophore-appended lanthanide complex sensitized via 
a ligand-centred triplet excited state (abs = absorbance; fluor. = 
fluorescence; phos. = phosphorescence; ISC = intersystem crossing; ET = 
energy transfer). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Basic information on the electronic transitions responsible for Ln(III) 
luminescence  
 
  Ground Emitting  Nature of 
 Ln(III) state state lem region emission 
 Pr 3H4 
1D2, 
3P0 Vis. and NIR Phos. and fluor. 
 Nd 4I9/2 
4
F3/2 NIR Fluor. 
 Sm 6H5/2 
4
G5/2 Vis. Phos. 
 Eu 7F0 
5
D0 Vis. Phos. 
 Gd 8S7/2 
6
P7/2 UV Phos. 
 Tb 7F6 
5
D4 Vis. Phos. 
 Dy 6H15/2 
4
F9/2 Vis. Phos. 
 Ho 5I8 
5
S2, 
5
F5 Vis. and NIR Fluor. 
 Er 4I15/2 
4
I13/2 NIR Fluor. 
 Tm 3H6 
1
D2, 
1
G4, 
3
H4 Vis. Phos. 
 Yb 2F7/2 2F5/2 NIR Fluor. 
       
 
However, the luminescence from Ln(III) ions originates from 4f–4f 
transitions, which are often sharp in appearance and are identi-fiably 
characteristic of the specific ion; emission can occur in the UV, 
visible or NIR regions (Table 1). The intraconfigurational 4f–4f 
transitions are formally forbidden, and thus possess very low molar 
absorptivities (e) limiting direct excitation, although a number of 
mechanisms (coupling with vibrational modes, J-state mixing and 
overlap with 5d orbitals and charge transfer states) can partially 
relax the (electric dipole) selection rules. The established strategy for 
overcoming this is to incorporate a sensitizing chromophore (also 
referred to as the antenna), which absorbs light and transfers energy 
to the 4f excited state via a mechanism that often involves the T1 
state of the sensitizer (Scheme 1). As a consequence of this 
mechanism the Stokes’ shift can be much larger than simpler organic 
systems, and is a function of the particular pathway for populating 
the 4f excited state. The overall quantum yields of emissive Ln(III) 
complexes depend on the sensitivity of 4f-centred excited states to 
O–H, N–H and C–H vibrational oscillators (particularly for the NIR 
emitting lanthanides), providing efficient non-radiative deactivation 
pathways (knr) and should be suppressed to enhance the emission, 
and the efficiency of energy transfer between the antenna and 
lanthanide ion.
11 
 
The forbidden nature of the 4f–4f transitions results in slow 
relaxation from the Ln(III) emitting state and thus long observed 
lifetimes (tobs). For aqueous solutions of DOTA-type Eu(III) and 
Tb(III) complexes, typical tobs values are ca. 1 ms; for NIR emitting 
Yb(III) and Nd(III) these values drop to ca. 1 ms and o1 ms, 
respectively. Er(III) emission is extremely sensitive to quenching by 
O–H, N–H, CQO and C–H oscillators
12,13
 and is very rarely 
observed in protic media.
14
 A critical advance in Ln(III) 
luminescence spectroscopy has been the use of time-resolved 
lifetime measurements in water and deuterated water (one assumes 
that O–D oscillators contribute minimally to knr) to approximate the 
inner sphere hydration (termed ‘q’) at Ln(III).
15
 Equations, which 
include both inner and outer sphere contributions, for the 
determination of q are known for Nd(III), Sm(III), Eu(III), Tb(III), 
Dy(III) and Yb(III) and have been sum-marised elsewhere.
11
 Care 
should be taken in the interpretation of calculated q values since 
errors are often significant (q 0.5). Of importance in this discussion 
is the fact that inner sphere hydration plays a very important role in 
determining the water 
 
 
 
proton relaxivity of a given Gd(III) complex (Section 3). There-fore it 
is common practice, for a given ligand, to isolate both luminescent 
Eu(III) and the analogous Gd(III) species, allowing correlation 
between luminescence and relaxometric assess-ments with respect to 
understanding lanthanide hydration.  
From an imaging perspective the antenna group defines labs and 
is a key component to consider in the design of Ln(III)-based agents’ 
compatibility with CFM excitation sources. For Eu(III) (
5
D0 B 17 
200 cm 
1
) and Tb(III) (
5
D4 B 20 400 cm 
1
), the triplet state of the 
antenna must lie 42000 cm 
1
 above the accepting Ln(III) state to 
allow sensitization and prevent back energy transfer (which can 
result in lowered emission intensity from the Ln(III)); a wide range of 
sensitising chromophores have been studied.
11 
 
Suitable antennae for Eu(III) and Tb(III) are commonly based upon 
polyaromatic or heterocyclic species, which absorb between 350–
410 nm, and possess small singlet–triplet energy gaps. For NIR 
emitting Ln(III) such as Yb(III) (
2
F7/2 B10 200 cm 
1
) the range of 
antennae is obviously broadened, with great imagination being 
applied to such systems that can range from donor–acceptor organics 
to transition metal complex moieties. Fig. 1 shows the structures of 
some reported antennae for sensitized emission; whilst acetophenone 
and naphthyl-type chromophores are good sensitisers for a wide 
range of Ln(III), it should be noted that pyrene, anthracene and 
anthraquinone antennae all possess triplet levels that lie below the 
accepting states of Eu(III) and Tb(III) and are better suited, therefore, 
to NIR emitting ions which possess lower lying accepting states. 
 
For imaging purposes Ln(III) complexes are also advantageous 
because of the dependence of the emission spectral form and lifetime 
on the coordination environment. Eu(III) is the exemplar in this 
context with sharp emission bands arising from 
5
D0 - 
7
FJ ( J = 0, 1, 
2, 3, 4) that are subtly sensitive to the nature and type of ligand 
donor and the coordination geometry at the ion. These properties 
enable the rational design of responsive probes (also referred to as 
sensors) where binding events at the Ln(III) ion can be interrogated 
directly using luminescence methods and ratiometric analyses (i.e. 
independent of probe concentration).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Examples of sensitising aromatic chromophores (antennae). 
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Scheme 2 Coordinative interaction of an anionic residue with a hydrated 
Ln(III)–DO3A complex.  
 
 
For example, Ln(III) ions have a strong aﬃnity for anions and direct 
binding to the Ln(III) ion typically occurs through a reversible 
intermolecular process (Scheme 2), inducing reversi-ble 
displacement of coordinated water molecules (i.e. q is reduced) 
resulting in measurable changes in luminescent output (e.g. relative 
and integrated intensities, and lifetime). An appre-ciation of anion 
binding aﬃnities and the resultant perturbation of the Ln(III) 
luminescence are very important in a biological context since 
various endogenous anionic residues are available for binding. 
 
Bioprobes based upon Ln(III) species must obviously possess the 
necessary physical properties to allow their application: water 
solubility, thermodynamic stability at physiological pH and kinetic 
inertness, photostability and minimal cytotoxicity are all highly 
desirable criteria. 
 
2.1 Lanthanide complexes as imaging labels 
 
Prior to their deployment in cell imaging studies, luminescent 
lanthanide complexes, particularly based on Eu(III), had clear 
precedent as optical labels through their use, over a number of 
decades, in sensitive bioanalyses such as DELFIA (dissociation-
enhanced lanthanide fluorometric immunoassay).
16
 More recently, 
luminescent macrocyclic Eu(III) complexes have been used to image 
and assess the extent of bone structure damage (microcracks). An 
amido-naphthalene group acts as the antenna and peripheral acetate 
groups target exposed Ca(II) sites of the hydroxyapatite  
 
lattice of the bone. CFM (Fig. 2) provided far greater fine detail of 
the bone surface morphology, through the observation of Eu(III)-
based red emission and improved signal contrast.
17 
 
Macrocyclic Ln(III) complexes can be successfully applied to 
time-resolved luminescence microscopy, as shown by comparing 
small diameter silica particles labelled either with cationic 
complexes of phosphorescent Eu(III) (Fig. 3) or rhodamine 6G (a 
fluorophore with a short fluorescence lifetime), which emits at 
similar wavelengths to Eu(III). The microscopy demonstrated that a 
microsecond time-delay allowed the Eu(III)-labelled silica particles to 
be easily diﬀ erentiated from those labelled with rhodamine 6G.18 
 
Bu¨nzli and co-workers have described an alternative class of 
luminescent complex: bimetallic, triple-stranded helical species of 
the general formula [Ln2L3] (Fig. 4) that form through self-
assembly.
19
 Both Ln(III) ions are tightly bound in a nonadentate 
coordination sphere, which limits any interaction with water. The 
complexes can be bioconjugated with avidin or monoclonal 
antibodies, allowing recognition of proteins expressed on the surface 
of breast cancer cells. These systems can be applied to ‘on-chip’ 
immunohistochemical detection methodologies.
20 
 
2.2 Cellular imaging with macrocyclic lanthanide complexes 
 
Both 1,3,5-triazacyclononane (TACN) and 1,4,7,10-tetraaza-
cyclononane (cyclen) provide excellent ligand scaﬀ olds for the 
development of Ln(III) based cell imaging agents, yielding 
complexes with high stability and kinetic inertness.  
Parker and co-workers have investigated the cellular ima-ging 
ability of a wide range of monometallic Ln(III)-based probes based 
on cyclen derivatives of Eu(III) and Tb(III).
21
 Each complex possesses 
a sensitizing chromophore (Fig. 5; e.g. tetraazatriphenylene, 
azaxanthone, azathiaxanthone), which is covalently linked to the 
cyclen framework. The periphery of the ligand architectures can be 
designed to dictate overall charge, influence lipophilicity and control 
cellular localisation.  
The dominant mechanism of cellular uptake for these cyclen 
complexes is macropinocytosis (the formation of large endo-cytotic 
vesicles of irregular shape and size). The nature and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 A polycarboxylate terminated Eu(III) complex (left) and microscopy images of bone sample immersed in 10 3  M solution of the complex.  
(a) Reflected light image: 0 h; (b) control; (c) 4 h; (d) 24 h. Reprinted with permission from McMahon et al., J. Am. Chem. Soc., 2009, 131, 17542. 
Copyright 2009 American Chemical Society. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Structures of the complexes (left) and a visible image and lifetime map for the Eu–DO3A derived complex loaded onto silica suspended in water.  
Reprinted with permission. Copyright 2000 Elsevier.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Ligands (left) for bimetallic helical complexes, and ‘on-chip’ immunohistochemical detection of Her2/neu and ER in a breast cancer tissue sample. 
(A) Bright field image; (B) merged luminescent image, Her2/neu detected by a green-emitting Tb(III) complex and ER stained with a red-emitting EuIII 
complex; (C) magnified image.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Examples of aromatic sensitizing chromophores used for CFM.  
 
linkage of the sensitizing chromophore is an important factor in 
determining cellular uptake and localization. The intra-cellular 
localization profile that is observed for the majority of these 
macrocyclic Ln(III) complexes is endosomal–lysosomal (confirmed 
through co-staining experiments with LysoTracker); generally the 
rates of uptake and egress are fast. Complexes that localized in the 
mitochondria for long periods of time (up to 10 h) demonstrated 
lower IC50 values (higher cytotoxicity).  
Monocationic Ln(III) complexes utilising azaxanthone-type 
chromophores in the 1- and 7-positions of the cyclen ring (Fig. 6) 
have shown selective staining of chromosomal DNA in 
dividing cells.
22
 The complexes possess low cytotoxicity (IC50 4  
400 mM), but single-photon illumination induces phototoxicity. 
Two-photon absorption may reduce such phototoxic eﬀ ects.  
Substituents added to an azaxanthone sensitizer dramati-cally 
influence the in cellulo traﬃcking behaviour of the probe. Simple 
structural changes that tune amphiphilicity reveal an element of 
control over cellular uptake, traﬃcking, localization and toxicity. 
More complex targeting vectors (Fig. 7) can also be conjugated to 
the azaxanthone antenna: peptide conjugates promote rapid 
internalization and cytosolic localisation; lipo-  
philic oligo-guanidinium vectors induced apoptotic cell death (IC50 
12 mM) following localization within mitochondria.  
With appropriate design, such complexes lend themselves to  
analytical approaches in a biological context. The ratiometric 
luminescence characteristics of Eu(III) 
5
D0 - 
7
FJ ( J = 0, 1, 2, 3, 4) 
can be exploited, using hyper-spectral analysis of microscopy 
images, to signal changes in intracellular biochemical species in real 
time. Eu(III) complexes (Fig. 7, right) that reversibly bind  
bicarbonate indicate a mitochondrial bicarbonate concentration of 
10–30 mM.
23 
 
Alternative chromophores based on a pyridylalkynylaryl group 
combine well with Eu(III) to provide high molar absorption 
coeﬃcients and eﬃcient sensitisation (Fig. 8). For example, a  
series of functionalised dipicolinate ligands react with Ln(III) to give 
tris-chelate complexes of the form [Ln(L)3]
3
 . The absorp-tion 
properties of the ligands can be tuned through the degree of charge 
transfer character imparted by the aryl substituent.
24
 Selected Eu(III) 
complexes of this type possess marked two-photon absorption cross-
section values (775 GM at 740 nm 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 The chromophorically 1,7-substituted complex (left) and a time course (5 min intervals) of microscopy images staining chromatin in a cell 
undergoing division (HeLa cells, Ln = Tb(III) complex, lex = 300 nm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Left: functionalising the periphery of the N-coordinated azaxanthone chromophore: hydrophilic (X = carboxylate and carboxamide), lipophilic  
(X = tertiary butyl, alkyl) and bio-inspired (X = LysArg, HSA, guan) variants. Right: an example of a mitochondrial localizing Eu-based probe.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 A Eu(III) complex incorporating a pyridylalkynylaryl chromophore.  
 
Fig. 8 Examples of donor-substituted dipicolinate ligands. 
 
 
excitation) in dichloromethane (note that such complexes usually 
dissociate in aqueous solutions).
25 
 
To address biocompatibility, a cyclen-based Eu(III) complex (Fig. 
9) incorporates both a pyridylalkynylaryl chromophore and two 
peptide sequences for targeting cyclin A (needed for stem cell cycle 
progression). The chromophore enables two-photon absorption at 12 
GM, which increased to 68 GM when the complex was bound to 
cyclin A allowing cell imaging 
 
in live HeLa cells using two-photon confocal microscopy (lex = 800 
nm).
26 
 
As discussed earlier, complexes based upon the cyclen 
framework have clearly yielded a significant range of Ln(III) imaging 
agents of great utility, the broader application of such species are 
often hampered by their intrinsically poor bright-ness, where 
brightness, B, is defined as B(l) = e(l)f (where e = molar absorption 
coeﬃcient; f = quantum yield). This limita-tion has been tackled 
through the design of tris-chromophoric derivatives of 
triazacyclononane (TACN) that bind the Ln(III) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 A mitochondrial staining Eu(III)–TACN complex.  
 
 
tightly and limit the approach of water solvent. Eu(III) com-plexes of 
TACN with three para-substituted pyridylalkynylaryl groups can 
possess impressive quantum yields (up to 50%) and large molar 
absorption coeﬃcients (450 000 M 1 cm 1) leading to very bright 
emission, even in aqueous solution. Although pyridylalkynylaryl 
groups possess lmax at 310– 340 nm, the magnitude of the absorption 
coefficient allows CFM with lex = 355 and 365 nm. The emission 
lifetimes of the Eu(III) complexes are typically around 1 ms, 
allowing time-gated (at 10 ms) images to be obtained.
27 
 
Variations in this core structural motif have allowed the 
development of a range of Eu(III)-based probes. A phosphinate-
derived Eu(III) complex (Fig. 10) has shown selectivity for staining 
mitochondria. Such complexes can be utilised as donor components 
in FRET (fluorescence resonance energy transfer) bio-assays, 
wherein the quenching of the Eu(III) signal is indicative of 
intermolecular energy transfer to an accepting near-IR dye (e.g. 
cyanine dye).  
The culmination of these diﬀ erent studies has resulted in the 
development of ‘EuroTracker’ dyes, variants of which are  
 
shown to give selective illumination of mitochondria, lysosomes or 
endoplasmic reticulum (ER).
28 
 
2.3 Bioimaging using multi-photon excitation sources 
 
The two-photon sensitization and imaging of a water-soluble Eu(III) 
complex has been reported with substituted 2,6-pyridinedi-
carboxylic acid type ligands (Fig. 11); the complex was surprisingly 
stable and strongly emissive in water (f B 16%) with a long lifetime 
(1.06 ms). T24 cancer cells were incubated with the complex and 
imaged using two-photon excitation at 760 nm (s2PA(760) = 19 
GM). Intracellular localization in the perinuclear region and the 
nucleus (which could be indicative of nucleoli targeting) was 
observed (Fig. 11).
29 
The development of acyclic ligand systems for Ln(III) ions has 
run in parallel with those myriad macrocyclic derivatives described 
earlier. In this context, Bu¨nzli’s self-assembled, triple-stranded 
helical complexes of the general form [Ln2L3] can be adapted for 
biological study. The hydrophilicity of these complexes can be 
controlled through the addition of poly-oxoethylene chains to the 
ligand periphery (Fig. 12).
30
 Similar approaches also allow 
bioconjugation and an element of control over cell permeability. The 
advantageous absorption and emis-sion properties of the [Eu2L3] 
species (excitation wavelengths tuned towards 400 nm, good 
quantum yields and long milli-second lifetimes in water) have 
allowed their application in CFM.  
Cancerous (HeLa, MCF-7, HaCat) and non-cancerous (Jurkat) 
cell lines have been investigated in the imaging studies. Uptake was 
generally defined through endocytosis with the Eu(III) com-plexes 
showing staining of the cytoplasm and liposomes of the ER.
31
 These 
complexes have also been applied to multi-photon excitation, with 
both two-photon (Fig. 13) and three-photon absorption exploited in 
an imaging context.
32
 Multi-photon absorption allows the use of 
longer wavelength excitation (e.g. NIR), which is more attractive 
when considering the optical window of biological material, and thus 
improving the depth of light penetration and resolution of 3D 
images.
4 
 
The significant potential of microscopy that utilises both NIR 
excitation and NIR emission
33
 has been demonstrated through the 
use of TPA of Yb(III)-containing probes with either 2,6-substituted 
pyridine ligands or TACN based scaﬀ olds,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11 The tris-picolinate complex core (left), with free ligand shown Inset. Two-photon excited luminescence (left, lex 760 nm) and phase contrast (right) 
images of T24 cancer cell fixed in ethanol and loaded with [Na]3[Eu(L)3]. Reprinted with permission from Picot et al., J. Am. Chem. Soc., 2008, 130, 1532. 
Copyright 2008 American Chemical Society. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12 Ligand utilized for the bimetallic helicate [Eu2L3] (R
1 = H, R2 = Me, R3 = PEG chain). Cells were incubated in presence of diﬀerent concentrations 
of the helicate in RPMI-1640 for 24 h. The images were taken using a Zeiss LSM 500 META confocal microscope (lex 405 nm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 Two-photon microscopy images of HeLa cells incubated with 200 mM of a bimetallic Eu(III) helicate in RPMI-1640 culture medium for 12 h at  
37 1C, 5% CO2: (a) bright field image; (b) luminescence (lex = 750 nm, lem = 570–650 nm); (c) merged image. Reprinted with permission from Eliseeva et 
al., J. Phys. Chem. B, 2010, 114, 2932. Copyright 2010 American Chemical Society.  
 
as described earlier for Eu(III); the antenna component in both cases 
is a pyridylalkynylaryl unit. In this case TPA sensitized Yb(III) 
emission required irradiation at 700–900 nm that populates the ILCT 
excited states of the antenna. Mouse brain slices were successfully 
imaged using a bespoke microscope set-up allowing two-photon 
NIR irradiation (760 nm) with detection at 1000 nm (corresponding 
to the Yb(III) 
2
F5/2–
2
F7/2 transition).
34 
 
2.4 Luminescent sensors in bioimaging 
 
The advantageous use of luminescent Ln(III) complexes as 
chemosensors
35
 (i.e. responsive systems) has been elegantly 
demonstrated in a biological context for targeting and imaging 
intracellular zinc. A diethylenetriamine pentaacetic acid (DTPA) 
ligand core was appended with a bridging quinoline-type 
chromophore, which was further functionalised with a dipicolyl-
amine unit (highlighted in red). For the Eu(III) complex, binding 
Zn(II) induced a 8.2-fold increase in quantum yield. The complex 
was then injected into HeLa cells and under normal levels of zinc 
showed no significant luminescence signal. However, upon addition 
of the zinc ionophore pyrithione and ZnSO4 the cell  
images brightened (Fig. 14) suggesting that the Eu(III) complex 
bound to Zn(II).
36 
 
An emissive Eu(III) complex can probe and image singlet oxygen 
(
1
O2) over other reactive oxygen species. Derived from an 
aminocarboxylate-based 2,2
0
:6
0
,2
00
-terpyridine ligand, which is 
substituted with a 9-anthryl unit (Fig. 15), the complex is weakly 
luminescent. Reaction with 
1
O2 converts the complex into a highly 
emissive species with long-lived luminescence. HeLa cells were co-
incubated with the complex and a 
1
O2 generating 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14 A Eu–DTPA derived complex (left) used as a zinc-responsive 
probe. The zinc binding site is indicated in red.  
 
 
porphyrin photosensitiser and imaged using time-gated lumi-
nescence microscopy. Following irradiation, rapid evolution of 
Eu(III)-based luminescence was localized in the nuclei.
37 
 
Parker and co-workers have previously reported
38
 the use of 
sulfonyl amine groups as pH dependent donors to Ln(III), yielding 
pH-responsive luminescent and relaxometric probes. This method 
has now been applied to the TACN-derived ligands described above, 
whereby one of the pyridylalkynylaryl donors was replaced with N-
methanesulfonylethylamine. Lifetime measurements on the Eu(III) 
complex revealed partial hydration (q 4 0) at pH 4 and zero 
hydration (q = 0) at pH 9, whilst the modulated fine structure of the 
spectral profile was indicative of an alteration in the Eu(III) 
environment (Fig. 16).
39 
 
It is important to note that a number of research groups
40
 have 
worked on the development of responsive luminescent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15 A 1O2 reactive Eu(III) complex (left). Bright-field (regions 1–3 are the centre regions of three HeLa cells, and region 4 is an extracellular region) 
and time-gated luminescence images of the Eu-deposited HeLa cells at different irradiation times. Reprinted with permission from Song et al. J. Am. 
Chem. Soc., 2006, 128, 13442. Copyright 2006 American Chemical Society.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16 A Eu(III)–TACN complex showing pH-sensitive luminescence.  
 
 
probes based on Ln(III) complexes. Some of the most promising 
systems
41
 seek to modulate q (as shown above for the pH response) 
upon analyte binding. Such systems should be espe-cially applicable 
to lifetime mapping microscopy (FLIM/PLIM), but have not been 
assessed under such conditions. 
 
 
3. Magnetic resonance imaging and 
contrast agents 
 
Magnetic resonance imaging (MRI) and computed tomo-graphy 
(CT) are the two most powerful radiological methods that are 
routinely used in the clinic. Both methods can provide 
 
 
finely detailed images, and with higher-field MRI becoming 
available, voxel resolutions of 100 mm are feasible. While standard 
hospital scanners (1.5 or 3 T) have a spatial resolu-tion of about 1 
mm and a time resolution of about a second, the current state of the 
art is the INUMAC imager.
42
 Containing an 11.75 T magnet and 
costing $270 M, it will be able to image to 100 mm and see 
biological processes occurring per one-tenth of a second. While in 
theory this state-of-the-art instrument may be useful for the early 
detection of neurode-generative disease, at the current cost it is hard 
to imagine its use on a world-wide stage, though one anticipates that 
technology will advance and costs of such magnets may diminish 
over time. 
 
 
 
       
       
Table 2  Comparison of diﬀerent imaging techniques     
       
Technique Resolution Depth Time Sensitivity Agents Primary use 
       
MRI 50–100 mm No limit min–h B10 6 M Gd, Dy, FenOm Versatile, high soft tissue contrast 
CT 50 mm No limit min B10 3 M Iodine Lung and bone 
Ultrasound 50 mm cm min  Microbubbles Vascular and interventional 
PET 1–2 mm No limit min B10 12 M 18F, 11C, 15O Versatile 
SPECT 1–2 mm No limit min B10 10 M 99mTc, 111In Labelled antibodies 
Fluorescence microscopy nm mm s  Fluorophores Cell work   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 Examples of common commercially available MRI contrast agents.  
 
 
MRI does not have the sensitivity of PET or SPECT, but it does 
have superior resolution (Table 2). However, the sensitivity (S/N) of 
MRI can be improved by the use of contrast agents (e.g. Fig. 17) and 
from a chemist’s view point, there is the added benefit that contrast 
agents may be designed to be responsive to their environment. With 
the possibility of switching the relaxation eﬀ ects, SMART contrast 
agents are feasible. This is particularly attractive to the research 
chemist and allows higher S/N and hence sensitivity. 
 
3.1 The basic MRI experiment 
 
In essence, by placing a water molecule in a field gradient, the 
1
H 
NMR resonant frequency of the protons in a water molecule is 
dependent upon the applied field. Thus, by placing a field gradient 
along the x then y and then z-axes, one is able to locate a water 
molecule in space. The true MRI experiment is a more complex 
situation, involving the spatial determination of all water molecules 
within the body, relying on the fact that water 
 
 
molecules in diﬀ erent parts of the body have diﬀ erent relaxa-tion 
rates and hence diﬀ ering signal intensities. In reality, the method 
requires significant data analysis, but the basic principles are the 
same as those familiar to NMR spectroscopy. 
 
The MR signal: common misconceptions in NMR and MRI. Due 
to a number of erroneous websites, many students think of the NMR 
signal as being due to the nucleus absorbing energy and nuclear spin 
moving from the z-axis to the z-axis. This, of course, is not the case. 
It is better to think of the nucleus as a small spinning magnet, which 
in a magnetic field aligns on the z-axis, but if we irradiate it with a 
pulse of energy (a 901 degree pulse) the spinning magnet moves into 
the xy plane. Now imagine a magnet on a piece of string: if you spin 
it around and bring it close to a wire coil, the spinning magnet will 
induce a current in the coil. This is the basis of NMR and thus MRI. 
 
Relaxation. Now, this spinning magnet in the xy plane does not 
stay there forever, and the signal is lost over time. Two main 
mechanisms cause a decay in the signal. One is the T1 relaxa-tion, 
referred to as longitudinal or spin–lattice relaxation and it involves a 
return of the nuclear dipole from the xy plane to the z-axis. The other 
is T2 relaxation, referred to as transverse or spin–spin relaxation. For 
this you must realise that, in the sample, all the nuclei spin (or 
precess) coherently in the xy plane. If this was not the case then there 
would be no net signal as it is the change in magnetic field that 
causes the signal and a totally random array of spins in the xy plane 
would result in no effective moment. The T2 relaxation relates to a 
dephasing of the net magnetic moment in the xy plane. In simple 
terms, a short T1 results in an increase in signal (as it allows us to 
rapidly apply 901 pulses to our sample) and a short T2 results in a 
decrease in signal. 
 
Contrast agents. In the MRI experiment, the diﬀ erence in signal 
intensity for the diﬀ erent compartments of the body may be small. In 
such cases, the addition of a contrast agent, specifically localised to 
an area of interest, will increase image resolution and sensitivity. 
 
Chemical reagents can aﬀ ect T1 and T2 to varying degrees. If a 
reagent aﬀ ects T1 to a greater extent it is a T1 or positive contrast 
agent which causes a stronger signal in its local vicinity, but if T2 4 
T1 then the opposite is true. While a number of diﬀ erent types of 
species have been reported as acting as eﬀ ective contrast agents, 
such as paramagnetic d-metal ions Mn(II) and Fe(III) complexes, 
organic radicals, and metal oxide nanoparticles, this review will 
focus upon the use of molecular lanthanide complexes. 
 
Positive contrast agents. These species primarily aﬀ ect the T1 
relaxation of solvent water molecules. Despite a few reports 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
of the use of f
7
 Eu(II) complexes, the overwhelming majority of T1 
molecular contrast agents are complexes of f
7
 Gd(III). By 
understanding the theory relating to T1 relaxivity and the 
prerequisites for in vivo use, the design of Gd(III) complexes will 
become clear, as will the current themes in the development of new 
reagents. 
Relaxation theory. The ability of a reagent to aﬀ ect the T1 of 
bulk water is expressed as its relaxivity (r1). The r1 of a complex is 
inversely related to the T1 relaxation time for a solution of agent: 
 
r1(obs) = 1/T1(obs) (1) 
 
the second term relates to the ability of the complex to relax the 
bound water molecules and propagate this eﬀ ect to the bulk solution. 
The relaxation of bound water (T1m) is governed by magnetic field 
dependent dipole–dipole (DD) and scalar/ contact mechanisms (SC) 
and for longitudinal relaxation SC mechanisms provide a negligible 
contribution. Solomon– Bloembergen–Morgan theory allows us to 
identify important parameters that affect T1m and hence r1. DD 
interactions are modulated by the reorientation of the nuclear spin–
electron spin vector, electron spin relaxation and the water/proton 
exchange rate. 
 
 
3.2 Optimising relaxivity 
 
 
r1(obs) = 1/T1(diamagnetic) + r1[Gd]  
 
r1 = r
IS
1 + r
OS
1 + r
SS
1
From this, we can see that for the optimisation of relaxivity (r1) we can 
target: (i) the q number; (ii) rotational correlation time, tr; (iii) the water 
exchange rate; (iv) S (total spin quantum number) and T1e (spin–lattice 
electronic relaxation time); (v) second sphere relaxivity. Each of these 
factors is discussed separately below. 
 
 
 
(i) The q number. As discussed earlier in the context of 
lanthanide luminescence, the q number can fundamentally 
influence the physical properties of the complex (Scheme 3). 
From eqn (4), it can be seen that this is the number of water 
molecules coordinated to the lanthanide centre and that the 
observed relaxivity is linearly proportional to q. However, in 
practice, we cannot and do not simply increase q to obtain 
maximal relaxivity. There are several reasons, discussed                                                       
below,              why this is not practical, desirable or optimal. 
where r
IS
1 is the inner sphere relaxivity due to the interaction 
between Gd(III) and water protons in the first coordination sphere 
(the eﬀ ect is transmitted to the bulk solution via chemical exchange 
of the inner sphere protons); r
OS
1 is the outer sphere relaxivity due 
to the bulk solvent molecules diﬀ using around the paramagnetic 
centre experiencing a para-magnetic eﬀ ect (relaxation due to the 
random translation diﬀ usion is outer sphere relaxation); rSS1 is 
second sphere relaxivity. Water may also hydrogen bond to the 
ligand or the inner sphere water and in theory, it may be treated the 
same as inner sphere relaxation. Separation of inner and outer sphere 
relaxation is based on the intra- and intermolecular nature of the 
interaction. In addition, it is diﬃcult to separate and evaluate the 
magnitude of second sphere relaxation as it appears as an increase in 
outer sphere relaxation. 
Typically for Gd(III) complexes r
IS
1 E r
OS
1, and while some 
work has focused on the variation of r
SS
1,
43
 most eﬀ orts aimed at 
modifying or increasing r1 involve the variation of r
IS
1.  
The inner sphere relaxivity is expressed by the equation: 
 
r1
IS
 = [cq/55.5] [1/T1m + tm] (4)  
here, c = conc. of gadolinium; q = number of bound water 
molecules; 55.5 is the concentration of water; T1m is longi-tudinal 
proton relaxation rate of bound water; tm = lifetime or residence 
time of inner sphere solvent.  
On reflection, it can be seen from eqn (4) that the first term is the 
mole fraction of water bound to the gadolinium, while 
Toxicity of ‘free Gd(III)’. GdCl3 is toxic with an LD50 of 100– 
200 mg kg 
1
 and it is deposited in the liver, bones and lymph system. 
However, by chelating a ligand to the metal, the toxicity of the 
imaging agent may decrease 4100 fold. However, the variation of 
toxicity between contrast agents varies greatly with the 
thermodynamic stability and/or kinetic inertness of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3 Cartoon representation of important parameters of a q = 2 
complex that influence relaxivity. 
 
 
  
 
Hence, r1 may be determined by measuring r1(obs) for varying 
concentrations of contrast agent. A plot of r1(obs) versus [Gd] will 
have a gradient of r1. Conventionally, the concen-tration is expressed 
as mM and hence the units of relaxivity are mM 
1
 s 
1
. The value is 
both field and temperature dependent and these parameters must be 
stated when r1 is reported. This value of r1 may be further segregated 
into its components: 
 
but the observed T1 has two components, one being the inherent  
relaxivity of the water solution and the other compo-nent due to the 
interaction between water molecules and the contrast agent. There is a 
linear relationship between contrast agent concentration and this 
component to relaxivity: 
  
 
 
 
 
 
 
 
 
 
 
 
the complexes. That is, if a metal is (i) firmly attached to the ligand 
(thermodynamic stability) or the metal is very slow at dissociating 
from the ligand (kinetic inertness), then one expects this complex 
will be less toxic. Thus, [Gd(H2O)8]
3+
 may have a moderately high 
relaxivity, but it would be toxic at the concentrations utilised in the 
clinic. Therefore a range of ligands has been developed by chemists 
for the encapsulation of lanthanide ions for use in luminescence, 
PET and MRI applications (some of which were discussed earlier). 
Clinically utilised reagents are typically derived from two families 
of ligands: acyclic, polydentate ligands based upon the DTPA 
framework which possess high thermodynamic stability, or cyclic 
polydentate ligands based upon a DOTA framework (Fig. 18) which 
possess both high thermodynamic stability and high kinetic 
inertness. However, to obtain this high stability, the ligands are often 
seven or eight coordinate meaning that q will be 2 or 1. Often, in 
designing a new ligand, one anticipates that the higher the value of 
q, the lower the stability may be. Thus the design of a new ligand is 
a careful balancing act of trying to lower ligand denticity, while 
trying to retain or improve the stability of the complex. Even once a 
new complex has been identified, there is still a possibility that when 
the complex is placed in biological media a ternary complex may 
form, with for example, a phosphate ion replacing bound water 
molecules and so reducing q and the observed relaxivity. 
 
 
 
Clinically utilised ligands, q values and stability constants. It is 
somewhat surprising that the majority of the clinically utilised 
ligands are based upon the DTPA ligand framework (Fig. 19), with 
DOTA and its related compounds being used to a lesser degree. For 
example in 2007, only B18% of the MRI contrast agents used were 
based on macrocyclic cyclen ligands, with Bracco’s Prohance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18 Selection of common macrocyclic ligands for Gd(III). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19 Example of acyclic ligands for Gd(III).  
 
 
being utilised less than Guerbet’s Dotarems. The most used contrast 
agent was Magnevist (Bayer Schering Pharma), with B51% followed 
by Omniscan (B25%, GE Healthcare).
44
 The thermodynamic 
stability of these compounds can be measured, by competitive acid–
base titrations, and the value is expressed as the log K (see Table 
3).
45 
 
Nephrogenic systemic fibrosis. First observed in 1997 and 
formally recognised in 2006, over time there have been increasing 
numbers of reports detailing the toxic eﬀ ects of Gd(III)-based 
contrast agents in patients who have impaired kidney function. 
Nephrogenic Systemic fibrosis (NSF) results in fibrosis of skin, 
joints, eyes, and internal organs, the condition may result in fractured 
bones or even death. It is considered that the release of free Gd(III) 
from the contrast agent is the root cause of NSF and Table 3 shows 
how the complexes with low stability constants have the highest 
incident of NSF. However, when comparing Magnevist to Dotarem, 
both have significant thermodynamic stability and it is the kinetic 
inertness of the latter which is seemingly beneficial. Currently, 
Omniscan and Optimark are considered to carry the greatest risk, 
followed by Magnevist and Multihance while Dotarem (using 
DOTA) and Prohance (using HPDO3A) are considered the less 
likely to release Gd. 
 
Ternary complexes. It is generally recognised that a high q 
number will result in a higher relaxivity. But even if one designs a 
new ligand resulting in a stable–inert complex with a low denticity, 
the resulting complex may still have a low q number. This is due to 
the formation of ternary complexes where a secondary ligand 
complexes to the metal centre displacing solvent water molecules. 
This is particularly problematic for cationic complexes which readily 
bind carboxylate and/or phosphate ions and was discussed earlier in 
the context of luminescence (Scheme 2). One approach is to develop 
ligands that give anionic Ln(III) complexes: the overall negative 
charge will electrostatically repel other anions in solution. 
 
Cage structures incorporating Gd(III). An ingenious approach to 
solving the problem of having a high q value without the toxicity, 
involves trapping the Gd(III) within a cage on the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
        
 Table 3  General properties of commercially available MRI contrast agents    
        
 Cases of NSF CAs admin. (millions) % of the market Incident/million doses Stability (log K) Dissoc. half-life 
        
 Omniscan 438 47 25.23 9.3 16.8 30 s 
 OptiMARK 7 0.8 0.43 8.8 16.8  
 Magnevist 135 95 50.99 1.4 22.2 10 min 
 MultiHance 0 6 3.22 0 22.6  
 Primovist 0 0.15 0.08 0   
 Vasovist 0 0.05 0.03 0   
 Gadovist 1 2.6 1.40 0.4   
 ProHance 1 12.3 6.60 0.1 23.8 3 h 
 Dotarem 1 22.4 12.02 0 25.6 338 h 
 Total 583 186.3 100 — — — 
         
 
 
 
molecular scale. The use of buckminsterfullerenes to surround the 
metal ion has proved successful, but the parent fullerenes required 
derivatisation to yield water soluble products. High relaxivities have 
been observed for alcohol derivatised fuller-enes (r1: Gd@C82(OH) 
is 67 mM 
1
 s 
1
 (298 K, 20 MHz, pH 7.5)), about 15 times greater 
than that of Magnevist,
46
 but the molecules do suﬀ er from 
significant reticuloendothelial system (RES) uptake. However, 
carboxylate functionalised analogues, although having a lower 
relaxivity,
47
 do not suﬀ er from this problem. It remains to be seen if 
the synthesis of such molecules could ever be carried out on a 
commercial scale, suitable for the pharmaceutical industry. 
 
(ii) The rotational correlation time, sr. Molecular motion causes 
local changes in the magnetic field and this has a signi-ficant eﬀ ect 
in changing the rate of relaxation. As described by SBM theory, 
proton relaxivity of small low molecular weight  
contrast agents may be limited by fast rotation and low hence low tr 
values (tr is the time taken to reorientate and high values  
indicate slow movement). This has prompted the development of 
new agents to slow down rotation and thus increase r1. 
 
Polymeric and dendrimeric structures. The Stokes–Einstein 
equation predicts tr to be proportional to r
3
 (where r is the effective 
radius of the molecule). Thus, the attachment of small molecule 
contrast agent, based on DTPA or DO3A, to a macro-molecular 
species will produce large species with long reorien-tation times. 
There are legions of polymers which have been utilised with this 
aim, but a key consideration would be the biocompatibility of the 
polymer. An example is the formation of DTPA–polyethyleneglycol 
species, with the two moieties conjoined by an amide link. 
Magnevist and Omniscan (Fig. 17) have tr values of 58 and 66 ps 
respectively, but upon the formation of the polymer (MW 20.2 kDa) 
there is a modest increase in tr to 232 ps,
48
 resulting in modest 
changes to r1 (6.31 mM 
1
 s 
1
, 20 MHz, 310 K; compared to 4.02 and 
3.96 mM 
1
 s 
1
 for Magnevist and Omniscan under similar 
conditions). An alternative ploy was the attachment of the contrast 
agent to a dendrimer, the advantage being that the dendrimer would 
have a well defined structure with a precise number of Gd(III) 
chelates attached at the periphery of the macromolecule. For 
example, the 3rd, 4th and 5th generation dendrimers possess 24, 48 
and 96 surface reactive groups allowing 23, 30 or 52 Gd(III) 
complexes to be attached. The resulting 
 
dendrimers have tr values of 580, 700 and 870 ps, respectively. 
While the resulting relaxivities are increased (14.6, 15.9 and 18.7 
mM 
1
 s 
1
, 20 MHz, 310 K),
49
 the values are still somewhat lower 
than one might expect. It was recognised that the nature of the 
chelate linker can allow rapid movement of the contrast agent: the 
slow rotational dynamics of the macromolecule are not transduced to 
the local Gd(III) chelates. Therefore it is important to consider the 
nature of the linker units and the rigidification of the Gd(III) 
chelate.
50 
 
Micelles and liposomes. As an alternative to covalently 
conjugating the contrast agent to a polymer, the association of a 
surfactant contrast agent to a micelle or liposome has also been 
explored. Hovland prepared an amphiphilic Gd-PCTA-[12] 
derivative which formed micelles in aqueous solution.
51
 With a 
relatively low critical micelle concentration (0.15 mM, 298 K), r1 is 
concentration dependent with a maximum relaxivity (29.2 mM 
1
 s 
1
, 
20 MHz, 298 K) occurring at 1 mM with micelle formation. The 
high relaxivity is a consequence of not only a long tr, but also a 
favourable water residence time.  
Similarly, Hovland also made highly lipophilic Gd(III) com-
plexes for liposome incorporation (Fig. 20).
52
 Using liposomes 
composed of cholesterol and phospholipids with short acyl chain 
lengths (DMPC and DMPG), the loading of Gd-chelate and the 
amount of cholesterol in the liposomes were varied and the relaxivity 
studied. The highest relaxivity (52 mM 
1
 s 
1
, 20 MHz) was found in 
liposomes with no cholesterol and a low content of Gd-chelate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 A lipophilic Gd(III)–PCTA derivative. 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Related to this, a low-density lipoprotein (LDL) particle was 
functionalized with a Gd–DO3A–monoamide chelate with a long 
alkenyl anchor. Intercalation into the lipid layer of the LDL particles 
led to a significant enhancement of the MRI signal of atheroplaques 
in atherosclerosis mouse models.
53 
 
Clearly, the interaction between the amphiphilic ligand and 
macromolecule in these examples is non-covalent and weak. One 
drawback of such species is that they will not exist at low 
concentrations and, in addition, the possible redistribution of the 
contrast agent to other structures when placed in the body cannot be 
ignored. In an attempt to form macromolecular contrast agents 
which are more stable, Wang carried out the mini-emulsion 
polymerization of a monomer along with amphiphilic Gd(III) 
metallosurfactants. Using DO3A or DTPA-based complexes, 
particles with a 20 or 48 nm diameter were formed (the structures 
were stable to a dilution to 0.02 mM)  
giving relaxivity enhancements of 11.1 mM 
1
 s 
1
 (from 4.3 mM 
1
 s 
1
) and 6.7 mM 
1
 s 
1
 (from 4.5 mM 
1
 s 
1
) for the respective reagents. 
The relaxivities were measured at 3 T (129 MHz), but no 
temperature was reported.
54 
 
Binding to receptors and surfaces. Perhaps one of the earliest and 
most impressive examples of how relaxivity can be increased upon 
lengthening tr was the increase observed when lipophilic Gd(III) 
complexes bound to blood protein. Aime has expanded upon his 
earlier work and recently reported a lipophilic Gd(III) chelate with a 
long aliphatic chain (Gd–AAZ-TAC17; q = 2, tm = 67 ns), with a 
relaxivity of 10.2 mM 
1
 s 
1
; at concentrations greater than 0.1 mM, 
the complex forms micelles (5.5 nm) with a relaxivity of B30 mM 
1
 
s 
1
 (20 MHz and 298 K).
55
 Gd–AAZTAC17 (Fig. 18) also exhibits 
good affinity for human serum albumin (HSA); the relaxivity shown 
by Gd–AAZTAC17/defatted HSA was 84 mM 
1
 s 
1
 (20 MHz, 298 
K) and is among the highest reported for a non-covalent para-
magnetic adduct with a slow-moving substrate. 
 
There are many other examples of restraining and attaching small 
Gd(III) complexes to large macromolecules, and these may be 
biological macromolecules (e.g. apoferritin), spore capsules and 
viral capsid or non-biological (e.g. gold nanoparticles or iron oxide 
nanoparticles). A recent example which serves as a thorough 
investigation of how slow tumbling of the Gd(III) centre aﬀ ects 
relaxivity, is a study of the binding of gadolinium complexes 
(compared to gadolinium ions) to a graphene oxide surface.
56
 The 
study indicates significant relaxivities for a Gd–DO3A–NH2 (Fig. 
18) complex when associated with the graphene oxide surface (r1 = 
B65 mM 
1
 s 
1
, B40 MHz), the value was approximately twice that of 
analogous Gd–DTPA–NH2 species (Fig. 19) and reflected the 
different q values in the two complexes (Gd–DO3A–NH2, q = 2; 
Gd–DTPA–NH2, q = 1). The study also emphasises the power of 
supporting nuclear magnetic resonance dispersion (NMRD) 
measurements: calculated para-meters (including tm and tr) can be 
obtained by fitting the variation in relaxation rate with varying 
applied magnetic field.  
We have already seen the example of Gd–AAZTAC17, a 
lipophilic molecule designed to interact with HSA and in doing so 
lengthen tr and significantly enhance the relaxivity. Perhaps 
 
the best example is the ligand MS325 developed by EPIX, who were 
liquidated in 2010 (once sold as Vasovist, it is now marketed as 
ABLAVAR by Lantheus Medical Imaging; Fig. 17). MS-325 (Fig. 
17) is a novel blood pool contrast agent to assess blockages in 
arteries. By strongly binding to HSA, the plasma half-life is 
lengthened, and r1 is increased due to a 60–100-fold increase in tr 
(10.1 2.6 ns vs. 115 ps free) upon binding.  
Another example of protein binding, also developed by EPIX, is 
the contrast agent EP-2104R (Fig. 21). It is an MRI contrast agent 
designed to detect blood clots by binding to the protein fibrin, 
present in all thrombi.
57
 EP-2104R comprises an 11 amino acid 
peptide derivatised with two Gd–DOTA-like moi-eties at both the C- 
and N-termini of the peptide. EP-2104R binds equally to two sites on 
human fibrin (Kd = 1.7 0.5 mM) and has excellent specificity for 
fibrin over fibrinogen (over 100-fold) and for fibrin over serum 
albumin (over 1000-fold). The relaxivity of EP-2104R bound to 
fibrin was 17.4 mM 
1
 s 
1
 (310 K and 60 MHz). Strong fibrin binding, 
fibrin selectivity, and high molecular relaxivity enable EP-2104R to 
detect blood clots in vivo. 
 
(iii) Water-exchange rates
58
. As shown in eqn (4), the rate at 
which water molecules bound to the Gd centre are exchanged with 
the bulk water is also of importance, as it is this exchange process (of 
water or protons) which allows the bulk to relax, not  
just those attached to the metal centre. In fact, there are many 
examples where tr has been optimised, but the gain in relaxivity is 
limited due to slow water exchange. Accordingly, significant work 
has sort to gain an understanding of the exchange process and 
determine how to control its rate. The mechanism by which this 
process occurs may be dissociative or associative, depending on the 
nature of the complex and the mechanism may be determined by 
measuring the volume of activation (a positive volume indicating a 
dissociative process). Simplifying the situation, an associative 
process will require a sterically  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21 Abbreviated structure of EP-2104R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 Water exchange parameters for common Gd(III) complexes  
 
 Complex ligand q Kex298 (  106 s 1) Mechanism 
 Aqua 8 804 A 
 DTPA 1 3.30 D 
 DTPA–NMA 1 1.3–1.9 D 
 DTPA–BMA 1 0.45 D 
 DOTA 1 4.1 D 
 DO3A 1.9 11  
 DO2A 2.8 10  
 DOTASA 1 6.3  
 TTAHA 2 8.6 D 
 PCTP-[12] 1 170 Ia 
      
 
non-demanding ligand, which will allow the metal to expand its 
coordination sphere, while rigid ligands yielding complexes with 
low q values will favour a dissociative process; Table 4 lists a 
variety of well known complexes and gives their mechanism if 
known. The rate of the process may be measured by studying the 
temperature dependent 
17
O NMR of aqueous solutions of these 
complexes.  
There are several points to note. It is the rigidity of the inner 
sphere coordination that is important and it is changes to the inner 
sphere that result in changes to the exchange rate. Compared to the 
aqua species, all Gd(III) amino carboxylates have much lower rates 
of exchange. Nearly all complexes go from 9 to 8 coordinate and 
this requires a high activation energy. The rigidity of the inner 
sphere plays an important role: replacing a carboxylate for an amide 
decreases the rate by a factor of 3–4 (e.g. DTPA vs. DTPA–NMA 
vs. DTPA–BMA). This may be explained by steric crowding, as the 
amide is less crowded, due to the longer Gd–O bonds. The steric 
crowding of the ligand pushes water away from the metal centre, 
easing the dissociation step. Exchange rates are hardly affected if 
substituent changes do not affect the inner coordination sphere. The 
charge on the complex is also important, with negatively charged 
complexes again facilitating the dissociative process. Accordingly 
DOTASA yields a complex with a 50% higher exchange rate 
compared to DOTA. In addition, the TTAHA complex has two 
water molecules, decreasing the inner sphere rigidity, and so 
increasing the exchange rate relative to the DTPA complex. 
However, the similar relaxivities of Gd–DO2A and Gd–DO3A, 
despite the lower inner sphere rigidity, may be ascribed to the 
adverse effect of the increased positive charge in the Gd–DO2A 
complex. Finally, with the exception of a few protein bound 
complexes, the inclusion of a monomeric Gd(III) chelate into a 
macromolecular/polymeric structure does not significantly affect 
water exchange kinetics. 
 
Finally, it is worth noting that while there is a general move-ment 
towards longer tr values and shorter water exchange rates, it should 
be remembered that there is a subtle interplay between these two 
parameters which requires some attention. Desreux has highlighted 
this point, showing that, with a low tr, the observed modest 
relaxivities do not change greatly if the water exchange rate changes 
(from one metal complex to another).
59
 But, when tr is much higher, 
the relaxivity is much more sensitive to the water exchange rate, and 
values which are both too high or too low are detrimental to the 
observed relaxivity. 
 
 
 
 
(iv) S and T1e. By definition, it is impossible to modify S if we 
are utilising Gd(III). Furthermore, for a mononuclear  
complex, S is optimal for Gd(III) and it is beneficial in having a long 
T1e which allows an eﬀ ective interaction between the relaxing 
electron of the metal ion and the relaxing nuclear spin of the proton. 
For a detailed discussion of the interaction of  
such spin systems, Luchinat has reviewed these interactions for a 
wide variety of metal ions.
60 
 
While it is diﬃcult to imagine how we may design modifica-tions 
of T1e in Gd(III) complexes, it is worth noting that the Gd–
AAZTAC17 complex mentioned above, forms micelles  
(5.5 nm) at concentrations greater than 0.1 mM, with a relaxivity of 
B30 mM 
1
 s 
1
 (20 MHz and 298 K). A relaxivity of 41 mM 
1
 s 
1
 was 
recorded when 98% of the Gd(III) ions were replaced by diamagnetic 
Y(III). In other words, the relaxivity is ‘‘quenched’’ by magnetic 
interactions between the Gd(III) ions on the surface of the micelle, 
causing a decrease in the electronic relaxation time. 
 
 
Second-sphere relaxivity
43
. Water associated with the contrast 
agent may be defined as inner sphere (directly coordinated to the 
metal) or outer-sphere (water molecules diﬀ using past the complex). 
The outer-sphere may often contribute 40–50% of the total relaxivity 
and largely depends on the distance of closest approach. Typically 
this does not vary too much for most compounds. However, there is 
an additional consideration to be made: some water molecules may 
be held close to the complex for longer than might be expected 
(longer than the diffusional correlation time) due to hydrogen 
bonding inter-actions with functional groups on the ligand. In such 
cases, the behaviour of these water molecules is described in the 
same way as an inner-sphere water molecule and it is difficult to 
discriminate the two. 
 
However, by careful choice of complex, e.g. complexes with q = 
0, it is possible to separate outer-sphere relaxivity from second 
sphere relaxivity. Aime et al. have carefully studied relevant 
complexes and in one example were able to show that a relaxivity 
enhancement upon binding with a protein was due to a number of 
second-sphere water molecules held about the Gd(III) centre.
61 
 
 
3.3 Responsive contrast agents 
 
As discussed earlier in the context of luminescent lanthanide 
complexes, an ability to report on the (biological) environment is 
highly desirable for in vivo imaging. With an understanding of how 
the relaxivity of a contrast agent may be modified or optimised, it is 
then possible to design responsive agents which can potentially 
allow in vivo imaging of chemical species or biological processes. 
While such ‘smart’ devices are yet to be used in the clinic, a number 
of compounds have been success-fully used in research and it is an 
avenue of contrast agent design which is understandably receiving 
much interest. Again, the following examples are in no way 
comprehensive, but they aim to give the reader an insight into how 
the appropriate ligand design can yield smart devices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22 Molecular structure of DTPA–SA.   
Fig. 23 Molecular structure of Gd–HADO–DO3A.  
 
 
 
Enzyme responsive. An early example of an enzyme respon-sive 
agent was prepared by Anelli et al.
62
 A novel Gd-DTPA derivative 
(Fig. 22) with a built-in sulfonamide (SA) was synthe-sized to 
selectively target the enzyme carbonic anhydrase. The longitudinal 
relaxation rates of aqueous solutions of Gd–DTPA–SA in the 
presence of carbonic anhydrase increased significantly. The complex 
interacts with erythrocytes, presum-ably due to a high affinity for the 
carbonic anhydrase present on their outer surface. The interaction of 
Gd–DTPA–SA with serum proteins was negligibly small so the 
complex may potentially be tested as a selective contrast agent for 
compart-ments outside the blood pool. 
 
Another example of enzyme responsive agents is Meade’s 
galactosidase-reactive complex. In this DO3A derivative, the ligand 
has a pendant galactopyranose group, which, when cleaved in the 
presence of galactosidase increases the q number of the complex. 
Beta-galactosidase is a commonly used marker gene, and thus 
regions of higher intensity in the MR image correlate with regions 
expressing marker enzyme. The contrast agent oﬀ ers promise of in 
vivo mapping of gene expression in transgenic animals and oﬀ ers a 
general approach for constructing a family of MRI contrast agents 
which can respond to biological activity.
63 
 
An alternative approach to measuring galactosidase expression 
was taken by Aime. In this approach, the contrast agent contains a 
galactose protected tyrosine group. Galactosidase produces a 
tyrosine group, which, in the presence of tyrosinase, yields a 
polymeric product with an accompanying increase in r1.
64 
 
pH responsive. There are many examples of pH-responsive 
contrast agents and often they are based upon the protonation and 
deprotonation of bound water ligands which perturb the water 
exchange rates, or the protonation/deprotonation of pendant 
amino/amido/alcohol groups which then modulate the q value. In 
addition, the protonation/deprotonation of polymer-based Gd(III) 
agents will adjust the polymeric structure and modify any observed 
relaxivity. For example, a 114-residue poly-ornithine with 30 
attached Gd–DO3A moieties and 84 pendant amines. In acid 
conditions, the amine groups are protonated and the structure is 
stretched out and flexible, but in basic conditions, the polymer 
shrinks and is more rigid: these changes in structure cause a 40% 
variation in the observed r1.
65 
 
Similarly, Hovland has prepared a series of Gd–DO3A deri-
vatives which mimic phospholipids. Two complexes were eval-uated 
as pH responsive MRI contrast agents in vitro. The T1 relaxivity (r1) 
of Gd–HADO–DO3A (Fig. 23) increased by 142% 
 
 
(to 18 mM 
1
 s 
1
, 10 MHz, 298 K) as the pH changed from 6 to 8. The 
pH dependence arises from the formation of supra-molecular 
structures caused by deprotonation of the amphi-philic complex at 
alkaline pH.
66 
 
Metal ion responsive agents. There are increasing numbers of 
reports of contrast agents which can selectively detect the presence 
of metal ions. The design of these complexes is often analogous to 
the related luminescent sensors (indeed lumines-cent lifetime 
measurements on Eu(III) analogues are frequently used to support 
relaxivity data on Gd(III) species),
67
 with the binding of the metal ion 
often modifying the q value of the Gd(III) centre. There has been 
particular interest in synthesising complexes which can detect 
biologically important analytes such as Zn(II), Cu(II), Fe(II) and 
Ca(II). Some examples of ligand design include a DTPA–BMA 
(Omniscan) derivative where the two ethylamide groups are replaced 
with 2,2
0
-dipicolylamine groups (Fig. 24).
68
 On addition of Zn(II) to 
the Gd(III) complex, the two dipicolylamine moieties come together 
to coordinate the Zn(II) molecule and in doing so hinder the access of 
water molecules to the Gd(III) centre. A reduction in relaxivity from 
6.06 to 3.98 mM 
1
 s 
1
 (300 MHz, 298 K) was observed when one 
equivalent of Zn(II) was added. No reduction in relaxivity was 
observed when Mg(II) or Ca(II) was added. 
 
A final example of Zn(II) detection utilises a DO3A ligand with a 
pendant iminodiacetate group (Fig. 24).
69
 In the absence of Zn(II), 
the acetates bind to the Gd(III) centre and restrict water access 
resulting in a low relaxivity (2.33 mM 
1
 s 
1
, 60 MHz). On addition of 
Zn(II) the relaxivity increases to 5.07 mM 
1
 s 
1
, consistent with one 
water molecule bound to Gd(III) (q = 1). Using this system, Zn(II) 
concentrations as low as 100 mM can be detected. No observed 
change in relaxivity was observed when either Ca(II) or Mg(II) were 
added. Interestingly, a similar ligand has been reported for the 
selective imaging of Cu(II).
70
 While it was stated that Zn(II) gave no 
enhancement of relaxivity, the experiment was run in phosphate 
buﬀ ered saline (PBS) and it is likely that the formation of insoluble 
zinc phosphate forms preferentially to the Gd–Zn adduct. 
 
 
 
4. CEST and PARACEST71 
 
A more recent addition to the field of MRI contrast agents is that of 
chemical exchange saturation transfer (CEST) agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24 Metal ion responsive Gd(III) agents.  
 
 
 
Building upon the original work of Ward et al.,
72
 a series of 
paramagnetic CEST agents have been synthesised and many of these 
agents contain a lanthanide centre.  
The basic approach may be understood by considering the fact 
that upon irradiating a given peak we will saturate its resonance, 
leading to a reduction in the signal. A CEST agent is a species with a 
labile proton, exchanging with bulk water. If the proton exchange 
rate is smaller than the separation of the two proton resonances, then 
the saturation of the CEST proton may be transferred to the bulk 
solution resulting in a depression of the bulk water signal. The rate 
of this exchange is important: naturally, we wish it to be as fast as 
possible, to enhance the exchange eﬀ ect, but the process must 
remain in the slow-intermediate exchange rate domain to ensure that 
two discrete resonances (bulk water and agent) are observed by 
NMR. 
The slow-intermediate exchange rate is defined as: DoCA/kCA 
c 1 where DoCA is the chemical shift diﬀ erence (in rad s 
1
) 
between the exchange site proton and water, and kCA is the rate of 
exchange.  
Unfortunately, when imaging the experiment cannot be quite so 
simple, as upon irradiation, a depression of the signal may be 
observed even without the CEST agent (due to the broad signal of 
proton in a biological matrix). To circumvent this problem, a 
secondary experiment is run, but this time irradiat-ing at the same 
distance form the water peak, but in the opposite direction. While a 
reduction in the water signal may be observed, it will be of a lesser 
magnitude to the first  
experiment. Now the saturation transfer (ST%) may be expressed as 
100 (1 Intensityon-resonance/Intensityoﬀ -resonance). The CEST agent’s 
eﬀ ectiveness is not measured by relaxivity, but instead can be 
measured by ST% compared to the agent concentration. 
 
These basic ideas have been greatly extended and have allowed a 
generation of new agents, namely PARACEST
73
 and LIPOCEST. A 
series of lanthanide complexes have been pre-pared and varying 
exchanging protons, have been investigated. These may be protons 
on waters bound to the metal centre, or they may be exchangeable 
protons on the ligand. Notable examples are the exchangeable –NH– 
peaks, which may be 
 
designed into a DTPA or DOTA type ligands via amide-type 
linkages. Furthermore, Aime
74
 has utilised complexes with two 
exchangeable protons (slowly exchanging water and NH on a ligand) 
to ratiometrically image pH (the two proton exchange rates differ in 
their response to pH). Obviously, these PARA-CEST agents are 
different to standard Gd(III) contrast agents, as they cause a dark 
image contrast, but there is significant interest in developing these 
agents as they offer the possibility of enhanced sensitivity. Sherry 
has recently comprehensively reviewed the subject of PARACEST 
agents.
75 
 
Finally, LIPOCEST agents
76
 are nanoparticular systems with 
extremely high numbers of mobile protons and so oﬀ er high 
contrast. More precisely, these are liposomes with hydrophilic 
lanthanide complexes, typically based on Dy(III) or Tm(III), trapped 
in the liposomal compartment. With up to 10
9
 mobile protons within 
the liposome, these reagents may show great sensitivity (o100 pM). 
 
 
 
5. Multimodal imaging 
 
As mentioned earlier, a number of imaging techniques are available 
at a biomedical level with various pros and cons associated with each 
(Table 4). Therefore combining two or more imaging modalities into 
a single molecule can circumvent many limitations associated with a 
particular technique, whilst simplifying aspects of the agent 
administration and bio-distribution characteristics 
(pharmacodynamics). The reader is directed to some recent excellent 
reviews that provide further details on a range of interesting 
examples, some of which include Ln(III) systems.
77–80
 Brief 
descriptions of examples incorporating lanthanide ions are 
highlighted below. 
 
MR/optical probes 
 
In essence a large number of chromophore appended Gd(III) 
complexes, which are synthesised as analogues of Eu(III) species, 
have the potential to deliver both MR and optical imaging 
capability.
81
 However, the residual fluorescence characteristics of 
the chromophore are often non-ideal for biological applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25 Examples of multimodal agents that contain Gd(III).  
 
 
 
A simple approach is to covalently link common biocompatible 
organic fluorophores (e.g. fluorescein or bodipy
82
) to DOTA-type, 
or similar, Gd(III) chelates: a large number of putative dual modal 
MR/optical imaging agents have been reported using such an 
approach. Long and co-workers have reported rhodamine function-
alised Gd(III) complexes based on a DOTA framework.
83
 The 
compound shown in Fig. 25 is water soluble (aided by the amide 
functionality), has r1 = 3.84 mM 
1
 s 
1
 (9.4 T, 298 K), and shows pH-
sensitive, rhodamine-centred fluorescence. The probe was cell 
penetrating and localised in the mitochondria of HEK (human 
embryonic kidney) cells, whilst imaging with 4.7 T MRI was 
obtained on nude mice with xenografted tumour implants. 
 
MR/radionuclide probes 
 
A number of innovative systems have been described that com-bine 
radionuclides with Gd(III) chelates. The common challenge is the 
time-limiting synthesis and purification associated with the isotope 
labelling step, which should be completed within 3 t1/2 (half-life) for 
the chosen radionuclide (for 
18
F, t1/2 is 109.8 min); ‘Click 
Chemistry’ is a popular means for adding radiolabels quickly and 
eﬃciently. Fig. 25 shows an example of such an approach that 
couples 
18
F with a traditional Gd(III) macrocyclic chelate to give a 
MR/PET probe.
84
 A single molecule SPECT/MR agent has also 
been reported that incorporates both 
99m
Tc and Gd(III) into a 
heterotrimetallic array based on a DTPA core.
85
 It should be noted 
that the large disparity in sensitivity between MRI and PET means 
that the former requires a much higher dosage for in vivo imaging. 
 
 
Radionuclide/optical probes 
 
Dual radionuclide and optical imaging probes are typically 
dominated by fluorophore-functionalised PET/SPECT agents. 
However, lanthanide systems have much to oﬀ er in this context. For 
example, it is possible to couple Gd–DO3A–AM chelates to a 
64
Cu 
porphyrin, potentially giving a trimodal 
 
MR(Gd)/PET(
64
Cu)/optical(porphyrin) agent.
86
 Of course it is also 
possible to imagine the combination of a luminescent lanthanide 
with a radioisotope (e.g. 
18
F) labelled ligand archi-tecture in a 
manner akin to the structures in Fig. 25. 
 
6. Comments and conclusions 
 
The development of lanthanide coordination chemistry in the context 
of applied biological imaging has been profound. The unique 
magnetic and optical physical properties of the lantha-nide ions have 
found great application in the design of probes that not only image, 
but can report on their local environment. Much of the chemistry 
associated with polyazacarboxylate Gd(III) MR contrast agents is 
mature (although the toxicity related problems of DTPA derivatives 
remains a concern), but some of the most interesting and imaginative 
developments now involve the design of multi-modal single 
molecule agents that incorporate Gd(III). Whilst Eu(III) dominates in 
the optical microscopy applications of lanthanide systems, 
optimisation of NIR emissive species, which oﬀ er the greatest 
potential in optical microscopy, remains a challenge. However, 
advances in detection hardware and the use of multi-photon light 
sources may allow greater imaging depths to be achieved when 
moving from cells to tissue analysis.
4
 Another area in which 
lanthanide ions can be expected to play an important role is in 
potential theranostic (therapy and diagnostics) agents, since the 
ability to image and deliver therapeutic action in a targeted manner 
will be of profound importance with respect to perso-nalised 
healthcare. 
 
Taken together a huge amount has been achieved with lanthanide 
ions thus far, and we hope that the selected examples presented in 
this review stimulate the interest for further reading. The future 
development of new agents for biomedical imaging, together with 
the advancement of new imaging tech-niques, will undoubtedly see 
lanthanide ions continue to play a 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
pivotal role in the design of next generation imaging and therapeutic 
agents. 
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